Researchers found preoperative blood glucose levels were associated with hospital length of stay for patients undergoing laparoscopic nephrectomy for RCC.
Rate of disease-free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy.
The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other VHL-associated tumors.
The approval was based on data from the pivotal phase 3 CLEAR (Study 307)/KEYNOTE-581 trial.
Treatment-naïve patients had better outcomes than previously-treated patients.
Decisions of how to proceed when positive surgical margins are found after partial nephrectomy are left to the discretion of the surgeon.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
A retrospective study identified factors that influenced overtreatment and undertreatment among patients with kidney cancer.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
Pembrolizumab plus axitinib improved progression-free and overall survival.
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
A meta-analysis of phase 3 randomized control trials sought to identify the TRAEs associated with 7 therapeutic regimens for the treatment of mRCC.
A review of retrospective data sought to better understand the relationship between obesity and survival in renal cell carcinoma.